The search for new antimicrobials: why we need new options

References

• Zinner SH, Wise R, Moellering RC Jr. Maximizing antimicrobial efficacy/minimizing antimicrobial resistance: a paradigm for the new millennium. Clin. Infect. Dis. 33(Suppl. 3) S107–S260 (2001).
   PubMedGoogle Scholar
• Memish ZA, Venkatesh S, Shibl AM. Impact of travel on international spread of antimicrobial resistance. Int. J. Antimicrob. Agents 21, 135–142 (2003).
   PubMed Web of Science ®Google Scholar
• Duckro AN, Blom DW, Lyle EA et al. Transfer of vancomycin-resistant enterococci via healthcare worker hands. Arch. Intern. Med. 165, 302–307 (2005).
   PubMedGoogle Scholar
• Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg. Infect. Dis. 7, 178–182 (2001).
   PubMed Web of Science ®Google Scholar
• Jacobs MR. Streptococcus pneumoniae: epidemiology and patterns of resistance. Am. J. Med. 117(Suppl. 3A) S3–S15 (2004).
   Web of Science ®Google Scholar
• Shah AA, Hasan F, Ahmed S et al. Characteristics, epidemiology and clinical importance of emerging strains of Gram-negative bacilli producing extended-spectrum β-lactamases. Res. Microbiol. 155, 409–421 (2004).
   PubMed Web of Science ®Google Scholar
• Hecht DW. Prevalence of antibiotic resistance in anaerobic bacteria: worrisome developments. Clin. Infect. Dis. 39, 92–97 (2004).
   PubMed Web of Science ®Google Scholar
• Holmberg SD, Solomon SL, Blake PA. Health and economic impacts of antimicrobial resistance. Rev. Infect. Dis. 9, 1065–1078 (1987).
   PubMedGoogle Scholar
• Linden PK. Clinical implications of nosocomial Gram-positive bacteremia and superimposed antimicrobial resistance. Am. J. Med. 104, S24–S33 (1998).
   Google Scholar
• Jacobs MR, Johnson CE. Macrolide resistance: an increasing concern for treatment failure in children. Pediatr. Infect. Dis. J. 22(8 Suppl) S131–S138 (2003).
   Web of Science ®Google Scholar
• Goldstein EJ, Garabedian-Ruffalo SM. Widespread use of fluoroquinolones versus emerging resistance in pneumococci. Clin. Infect. Dis. 35, 1505–1511 (2002).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Vancomycin-resistant Staphylococcus aureus – New York, 2004. Morb. Mortal. Wkly Rep. 53, 322–323 (2004).
   PubMedGoogle Scholar
• Barber M. Methicillin resistant staphylococci. J. Clin. Pathol. 14, 385–393 (1961).
   PubMed Web of Science ®Google Scholar
• Panlilio AL, Culver DH, Gaynes RP et al. Methicillin-resistant Staphylococcus aureus in US hospitals, 1975–1991. Infect. Control Hosp. Epidemiol. 13, 582–586 (1992).
   PubMed Web of Science ®Google Scholar
• Diekema DJ, Pfaller MA, Schmitz FJ et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific Region for the SENTRY antimicrobial surveillance program, 1997–1999. Clin. Infect. Dis. 32, 114–132 (2001).
   PubMed Web of Science ®Google Scholar
• National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am. J. Infect. Control 31, 481–498 (2003).
   Google Scholar
• Weber SG, Gold HS, Hooper DC et al. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg. Infect. Dis. 9, 1415–1422 (2003).
   PubMed Web of Science ®Google Scholar
• Wong SS, Ng TK, Yam WC et al. Bacteremia due to Staphylococcus aureus with reduced susceptibility to vancomycin. Diagn. Microbiol. Infect. Dis. 36, 261–268 (2000).
   PubMed Web of Science ®Google Scholar
• Edmond MB, Wenzel RP, Pasculle AW. Vancomycin-resistant Staphylococcus aureus: perspectives on measures needed for control. Ann. Intern. Med. 124, 329–334 (1996).
   PubMed Web of Science ®Google Scholar
• Fridkin SK, Hageman JC, Morrison M et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N. Engl. J. Med. 352, 1436–1444 (2005).
   PubMed Web of Science ®Google Scholar
• Anonymous. Four pediatric deaths from commmunity acquired methicillin-resistant Staphylococcus aureus – Minnesota and North Dakota, 1997–1999. Morb. Mortal. Wkly Rep. 48, 707–710 (1999).
   PubMedGoogle Scholar
• Kazakova SV, Hageman JC, Matava M et al. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N. Engl. J. Med. 352, 468–475 (2005).
   PubMed Web of Science ®Google Scholar
• Steward CD, Raney PM, Morrell AK et al. Testing for induction of clindamycin resistance in erythromycin-resistant isolates of Staphylococcus aureus. J. Clin. Microbiol. 43, 1716–1721 (2005).
   PubMed Web of Science ®Google Scholar
• Karchmer AW. Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US – an update. Clin. Infect. Dis. 39(Suppl. 3) S142–S150 (2004).
   PubMed Web of Science ®Google Scholar
• Low DE. Quinolone resistance among pneumococci: therapeutic and diagnostic implications. Clin. Infect. Dis. 38(Suppl. 4) S357–S362 (2004).
   PubMedGoogle Scholar
• Ambrose P, Bast D, Doern GV et al. Fluoroquinolone-resistant Streptococcus pneumoniae, an emerging but unrecognized public heatlh concern: is it time to resight the goalposts? Clin. Infect. Dis. 39, 1554–1556 (2004).
   PubMedGoogle Scholar
• Edelstein PH. Pneumococcal resistance to macrolides, lincosamides, ketolides, and streptogramin B agents: molecular mechanisms and resistance phenotypes. Clin. Infect. Dis. 38(Suppl. 4) S322–S327 (2004).
   Google Scholar
• Farrell DJ, Morrissey I, Bakker S et al. In vitro activities of telithromycin, linezolid, and quinupristin–dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations. Antimicrob. Agents Chemother. 48, 3169–3171 (2004).
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Palatnick L, Nichol KA et al. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob. Agents Chemother. 47, 1867–1874 (2003).
   PubMed Web of Science ®Google Scholar
• Feikin DR, Schuchat A, Kolczak M et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997. Am. J. Public Health. 90, 223–229 (2000).
   PubMed Web of Science ®Google Scholar
• Metlay JP, Hofmann J, Cetron MS et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin. Infect. Dis. 30, 520–528 (2000).
   PubMed Web of Science ®Google Scholar
• Fogarty C, Goldschmidt R, Bush K. Bacteraemic pneumonia due to multiresistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin. Clin. Infect. Dis. 31, 613–615 (2000).
   PubMed Web of Science ®Google Scholar
• Lonks JR, Garau J, Gomez L et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin. Infect. Dis. 35, 556–564 (2002).
   PubMed Web of Science ®Google Scholar
• Jones ME, Draghi DC, Thornsberry C et al. Emerging resistance among bacterial pathogens in the intensive care unit – a European and North American Surveillance study (2000–2002). Ann. Clin. Microbiol. Antimicrob. 3, 14 (2004).
   PubMedGoogle Scholar
• Kang CI, Kim SH, Park WB et al. Bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob. Agents Chemother. 48, 4574–4581 (2004).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bano J, Navarro MD, Romero L et al. Epidemiology and clinical features of infections caused by extended-spectrum β-lactamase-producing Escherichia coli in non-hospitalized patients. J. Clin. Microbiol. 42, 1089–1094 (2004).
   PubMed Web of Science ®Google Scholar
• Colodner R, Rock W, Chazan B et al. Risk factors for the development of extended-spectrum β-lactamase-producing bacteria in nonhospitalized patients. Eur. J. Clin. Microbiol. Infect. Dis. 23, 163–167 (2004).
   PubMed Web of Science ®Google Scholar
• Lautenbach E, Strom BL, Bilker WB et al. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin. Infect. Dis. 33, 1288–1294 (2001).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Siakavella S. Bacteroides, Prevotella, and Porphyromonas species. A review of antibiotic resistance and therapeutic options. Int. J. Antimicrob. Agents 15, 1–9 (2000).
   PubMedGoogle Scholar
• Snydman DR, Jacobus NV, McDermott LA et al. National survey on the susceptibility of Bacteroides fragilis Group: report and analysis of trends for 1997–2000. Clin. Infect. Dis. 35(Suppl. 1) S126–S134 (2002).
   Google Scholar
• Golan Y, McDermott LA, Jacobus NV, Emergence of fluoroquinolone resistance among Bacteroides species. J. Antimicrob. Chemother. 52, 208–213 (2003).
   PubMed Web of Science ®Google Scholar
• Hedberg M, Nord CE; ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe. Clin. Microbiol. Infect. 9, 475–488 (2003).
   PubMed Web of Science ®Google Scholar
• Elsaghier AA, Brazier JS, James EA. Bacteraemia due to Bacteroides fragilis with reduced susceptibility to metronidazole. J. Antimicrob. Chemother. 51, 1436–1437 (2003).
   PubMedGoogle Scholar
• Nguyen MH, Yu VL, Morris AJ et al. Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial. Clin. Infect. Dis. 30, 870–876 (2000).
   PubMed Web of Science ®Google Scholar
• Solomkin JS, Mazuski JE, Baron EJ et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin. Infect. Dis. 37, 997–1005 (2003).
   PubMed Web of Science ®Google Scholar
• Doern GV, Jones RN, Pfaller MA et al. Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). SENTRY study group (North America). Diagn. Microbiol. Infect. Dis. 34, 65–72 (1999).
   PubMed Web of Science ®Google Scholar
• Lipsky BA. Medical treatment of diabetic foot infections. Clin. Infect. Dis. 39(Suppl. 2) S104–S114 (2004).
   PubMed Web of Science ®Google Scholar
• Combes A, Figliolini C, Trouillet JL et al. Incidence and outcome of polymicrobial ventilator-associated pneumonia. Chest 121, 1618–1623 (2002).
   PubMedGoogle Scholar
• Raghavan M, Linden PK. Newer treatment options for skin and soft tissue infections. Drugs 64, 1621–1642 (2004).
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies. Am. J. Respir. Crit. Care Med. 153, 1711–1725 (1996).
   PubMed Web of Science ®Google Scholar
• Lodise TP, McKinnon PS, Swiderski L et al. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin. Infect. Dis. 36, 1418–1423 (2003).
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Homenuik K, Nichol K et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs 64, 63–88 (2004).
   PubMed Web of Science ®Google Scholar
• Pankey GA. Tigecycline. J. Antimicrob. Chemother. 56(3) 470–480 (2005).
   PubMed Web of Science ®Google Scholar
• Ellis-Grosse EJ, Babinchak T, Dartois et al. The efficacy and safety of tigecycline in the treatment of skin and skin structure infections: results of two double-blind Phase 3 comparison studies with vancomycin/aztreonam. Clin. Infect. Dis. (2005) (In press).
   Google Scholar
• Babinchak T, Ellis-Gross E, Dartois N et al. The efficacy and safety of tigecycline in the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin. Infect. Dis. 41(Suppl 5) S354–S367 (2005)
   PubMed Web of Science ®Google Scholar
• Spellberg B, Powers JH, Brass EP et al. Trends in antimicrobial drug development. Clin. Infect. Dis. 31, 1279–1286 (2004).
   Google Scholar
• Guay DR. Dalbavancin: an investigational glycopeptide. Expert Rev. Anti Infect. Ther. 2, 845–852 (2004).
   PubMedGoogle Scholar
• Mercier RC, Hrebickova L. Oritavancin: a new avenue for resistant Gram-positive bacteria. Expert Rev. Anti Infect. Ther. 3, 325–332 (2005).
   PubMedGoogle Scholar
• Pace JL, Judice JK. Telavancin (Theravance). Curr. Opin. Investig. Drugs 6, 216–225 (2005).
   PubMedGoogle Scholar
• Wise R. The relentless rise of resistance? J. Antimicrob. Chemother. 54, 306–310 (2004).
   PubMedGoogle Scholar